About 470 results

ALLMedicine™ Chronic Anemia Center

Research & Reviews  162 results

Iron overload and iron chelating agent exposure in anemia-associated outer retinal dege...
BMC Ophthalmology; Belmouhand M, Eckmann-Hansen C et. al.

Jul 15th, 2021 - Deferoxamine retinopathy is the informally designated term used to describe a characteristic pattern of outer retinal degeneration in iron-overloaded chronic anemia patients who are treated with deferoxamine. We hypothesize that insufficiently tre...

The different facets of sickle cell disease-related pulmonary hypertension.
Current Opinion in Pulmonary Medicine; Prohaska CC, Machado RF

Jul 6th, 2021 - Sickle cell disease (SCD), one of the most common genetic diseases in the world, is characterized by repeated episodes of hemolysis and vaso-occlusion. Hemolytic anemia is a risk factor for the development of pulmonary hypertension, and currently ...

Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias.
American Journal of Hematology; Vu C, Bush A et. al.

Apr 24th, 2021 - Anemia is the most common blood disorder in the world. In patients with chronic anemia, such as sickle cell disease or major thalassemia, cerebral blood flow increases to compensate for decreased oxygen content. However, the effects of chronic ane...

Association between red blood cell transfusion dependence and burden in patients with m...
European Journal of Haematology; Braga Lemos M, Rodrigues SR et. al.

Mar 15th, 2021 - Myelodysplastic syndromes (MDS) are a group of malignant hematologic diseases characterized by ineffective hematopoiesis, which may lead to chronic anemia and transfusion dependency, with up to 30% of patients progressing to acute myeloid leukemia...

Efficacy and Safety of Sirolimus for Blue Rubber Bleb Nevus Syndrome: A Prospective Study.
The American Journal of Gastroenterology; Zhou J, Zhao Z et. al.

Jan 9th, 2021 - Blue rubber bleb nevus syndrome (BRBNS) is a rare systemic venous malformation (VM) disease. The characteristic gastrointestinal (GI) bleeding from multiple VM lesions causes severe chronic anemia which renders most patients depend on lifelong blo...

see more →

Clinicaltrials.gov  9 results

Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia

Mar 18th, 2020 - This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its ...

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

Oct 24th, 2018 - Sickle cell disease (SCD) is a genetic disease that afflicts over eighty thousand Americans, 4 to 5,000 newborns per year in the US, and 100s of thousands of children and adults world-wide. This disease arises from a single amino acid mutation of ...

Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Wit...

Jul 12th, 2018 - Sickle cell disease is a genetic disease responsible for an abnormal hemoglobin. It particularly affects populations with an African ascent (300 000 African children are born every year with this genetic anomaly). The anomaly has several consequen...

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

May 31st, 2018 - Despite the significant improvements in the therapeutic management of beta thalassemia major (BTM) over the past few decades, osteoporosis is still a common finding, even in optimally treated patients. The relationships between bone mineral densit...

The Congenital Dyserythropoietic Anemia Registry (CDAR)

Nov 27th, 2017 - To establish and maintain a CDA registry (CDAR): a comprehensive registry of subjects with the diagnosis of any type of congenital dyserythropoietic anemia in North America. Subjects and their physicians have expressed interest in participating in...

see more →

News  17 results

Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia

Jun 13th, 2021 - The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) transfusions. Now it has also shown to be beneficial for...

Fast Five Quiz: Are You Prepared to Confront Sickle Cell Disease?

Nov 2nd, 2020 - Urgent replacement of blood is often required for symptomatic anemia due to parvovirus B19 infection or acute splenic sequestration. Transfusions are not needed for asymptomatic chronic anemia or worsening anemia occurring during episodes of pain ...

My Job Isn't to Move Patients Quickly

Mar 8th, 2018 - "We are playing the same sport, but a different game," the wise, thoughtful emergency medicine attending physician once told me. "I am playing speed chess -- I need to make a move quickly, or I lose -- no matter what. My moves have to be right, bu...

Drug nets orphan designation for beta-thalassemia
HT Staff

Mar 8th, 2018 - thalassemia Micrograph showing The US Food and Drug Administration (FDA) has granted orphan drug designation to PTG-300, a subcutaneous injectable hepcidin mimetic, for the treatment of beta-thalassemia. Protagonist Therapeutics, the company devel.

Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia
William E Strauss et al

Aug 24th, 2016 - Background Many patients with iron deficiency anemia (IDA) do not tolerate or adequately respond to oral iron and live with chronic anemia and related negative effects on health-related quality of life (HRQoL). However, data from double-blind, pla.

see more →